期刊文献+

诱骗受体3在上皮性卵巢癌组织中的表达及临床意义 被引量:6

Expression of decoy receptor 3 in epithelia ovarian carcinoma and its clinical significance
下载PDF
导出
摘要 目的:诱骗受体3(decoy receptor 3,DcR3)是肿瘤坏死因子受体(TNFR)家族的成员,影响着多种肿瘤的发生发展,本实验研究探讨其与卵巢癌发生发展及预后的关系。方法:应用免疫组织化学SP法检测38例正常卵巢组织、29例卵巢良性肿瘤及86例卵巢上皮性癌组织中DcR3蛋白的表达情况。结果:DcR3蛋白在卵巢癌组织中的表达明显高于卵巢良性肿瘤及正常组织中的表达;DcR3蛋白在卵巢上皮性癌Ⅰ-Ⅱ期表达较Ⅲ-Ⅳ期明显减弱;在高中分化组织中的表达明显低于低分化组织;在淋巴结转移组的表达高于无淋巴结转移组,各组间差异均具有统计学意义(P<0.05)。DcR3蛋白表达越强,患者生存时间越短(P<0.05)。结论:DcR3表达水平与卵巢上皮性癌临床分期、组织分化、肿瘤浸润、转移及预后有关,有可能成为一种卵巢癌肿瘤特异性指标。 Objective:Decoy receptor 3(DcR3),a new member of tumor necrosis factor receptor(TNFR)super-family,is not only upregulated in cancer cells derived from various cell lineages,but also correlates with the overall survival of certain cancer patients. We studied a possible association between DcR3 expression and prognosis in pa-tients with epithelial ovarian carcinoma. Methods:Protein expression of DcR3 was compared in 38 normal human o-varian tissues,29 benign ovarian tissues and 86 epithelial ovarian cancer( EOC)by immunohistochemistry( IHC). Re-sults:Expression of DcR3 in EOC was significantly higher than that in normal ovarian tissues(p〈0. 01)and benign ovarian tissues(p〈0. 05),respectively. It was also found that DcR3 expression in well differentiated EOC was signifi-cantly low than that in poorly differentiated specimens(p〈0. 05). Patients in stages I and II showed significantly low-er DcR3 expression compared with that in stages III and IV(p〈0. 05). DcR3 expression in lymph node metastasis-negative patients was significantly decreased in comparison with that in lymph node metastasis-positive patients( p〈0. 05). Conclusion:DcR3 protein expression is significantly over-expressed in malignant tumors compared to normal ovaries and benign tumors. While it is relatively unchanged in benign tumors compared to normal ovary. The DcR3 gene might serve as an important molecular biological indicator in diagnosing and predicating the clinical outcome in EOC patients.
出处 《现代肿瘤医学》 CAS 2015年第1期116-119,共4页 Journal of Modern Oncology
基金 黑龙江省教育厅科研项目(编号:12521312)
关键词 DCR3 卵巢癌 免疫组织化学 预后 DcR3 ovarian cancer immunohistochemical prognosis
  • 相关文献

参考文献16

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [ J ]. CA Cancer J Clin ,2009,59 (4) :225 - 249.
  • 2Larsen IK, SmKstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway : an overview of comparability, complete- ness,validity and timeliness[ J]. Eur J Cancer,2009,45 ( 7 ) : 1218 - 1231.
  • 3Pitti RM, Masters SA, Lawrence DA, et al. Genomieamp lification of a decoy receptor for fas ligand in lung and colon cancer [ J ]. Na- ture,1998,396(6712) :699 -703.
  • 4Gill RM, Hunt JS. Soluble receptor( DeR3 ) and cellular inhibitor of apoptosis - 2 ( el "AP - 2 ) protect human Cytotrophoblast cells a- gainst LIGHTmediated apoptosis[ J]. Am J Patho1,2004,165 ( 1 ) : 309 -317.
  • 5Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplifi- cation and its location in a four- gene cluster[ J]. Proc Natl Acad Sei USA ,2000,97(3 ) : 1230 - 1235.
  • 6Ren Z,Zhu J,Gu H,et al. Decoy receptor 3 polymorphisms are not associated with the risk of esophageal cancer in a Chinese popula- tion[J]. Biomarkers,2014,5:2.
  • 7Yu W,Xu YC,Tao Y,et al. DcR3 regulates the growth and meta- static potential of SW480 colon cancer cells[ J]. Oneol Rep,2013, 30(6) :2741 -2748.
  • 8钟智强,兰小鹏,杨湘越,李卫滨,张鲁榕,朱忠勇.DcR3基因在原发性肺癌的扩增和表达及临床意义[J].福州总医院学报,2007,14(3):166-168. 被引量:2
  • 9Huang S, Chen G, Dang Y, et al. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma [J]. Sci World J,2014,60:236.
  • 10Ohshima K, Haraoka S, Sugiham M, et al. Amplification and ex- pressin of a decoy receptor for 3 ( DcR3 ) for Fas ligand in virus ( E6V or HTLV - 1 ) associated lymphomas [ J ]. Cancer Lett, 2000,160 : 89 - 97.

二级参考文献6

  • 1钟智强,兰小鹏.DcR3与肿瘤研究新进展[J].国外医学(肿瘤学分册),2005,32(5):323-326. 被引量:2
  • 2Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 1998, 396: 699-703.
  • 3Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DcR3 in human gastro -intestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA, 2000, 97: 1230-1235. 3 Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor
  • 4is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Research, 2001, 61:2759-2765.
  • 5Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem,1999, 274, 13733 -13736.
  • 6Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett, 2000, 160:89-97.

共引文献2

同被引文献29

  • 1王劲欧,吕庆杰,姜卫国,齐亚飞,夏光.DcR3在卵巢癌的表达及意义[J].肿瘤学杂志,2009,15(11):988-989. 被引量:3
  • 2Ao R, Du YQ, Wang Y, et al. MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival [J]. Int J Clin Exp Med, 2013,6(8) :700-705.
  • 3Huang S, Chen G, Dang Y, et al. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma [J]. Scientific World J, 2014.
  • 4Simon I, Liu Y, Krall KL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer [J]. Gynecol Oncol, 2007,106( 1 ) : 112-128.
  • 5Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance [J]. Gynecol Oncol, 2008, 111(2) :330-335.
  • 6Connor JP, Felder M, Kapur A, et al. DeR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1 [J]. BMC Cancer, 2012,12( 1 ) : 176.
  • 7SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014,64( 1 ) :9 -29.
  • 8SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2013 ~J]. CA Cancer J Clin, 2013,63(1) :11 -30.
  • 9HUNN J, RODRIGUEZ G C. Ovarian cancer: etiology, risk factors, and epidemiology[ J]. Clin Obstet Gynccol, 2012,55(1) :3 -23.
  • 10CRAMER D W. The epidemiology of endometrial and ovarian cancer [J]. Hematol Oncol Clin North Am, 20t2,26( 1 ) :1 - 12.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部